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Available online 24 October 2013Colorectal cancer (CRC) is the second leading cause of cancer deaths in the US and Western world.
Despite increased screening and advances in treatment, themortality rate (ca. 50,000/year) andhigh
national health-care burden for CRC are likely to remain high unless an effective non-invasive
screening test for CRC is instituted for a large segment of the population. Blood-based protein
biomarkers hold great promise for early disease diagnosis and personalized medicine; yet robust
and reproducible multiplexing platforms and methodologies have lagged behind their genomic
counterparts.
Here, we report the development of a novel, multiplexed, hybrid immunoassay for CRC that is
formatted onbarcodedVeraCode™micro-beads,which have until nowonly beenused for genomic
assays. The method combines a sandwich immunoassay format for detection of serum protein
biomarkers with an antigen assay for autoantibody detection. The serum protein biomarkers CEA
and GDF15 as well as autoantibodies to the p53 tumor associated antigen (TAA) were used to
exemplify the method. This multiplex biomarker panel was configured to run on Illumina's
holographically barcoded VeraCode™ micro-bead platform, which is capable of measuring
hundreds of analytes simultaneously in a single well from small volumes of blood (b50 μL)
using a 96-well industry standard microtiter plate. This novel use of the VeraCode™
micro-bead platform translates into a potentially low volume, high throughput, multiplexed
assay for CRC, for the purposes of biomarker validation, as well as patient screening,
diagnostics and prognostics. In an evaluation of a 186 patient sera training set (CRC and
normal), we obtained a diagnostic sensitivity of 54% and a specificity of 98%. We anticipate
that by expanding and refining the biomarkers in this initial panel, and performing more
extensive clinical validations, such an assay could ultimately provide a basis for CRC
population screening to complement the more invasive, expensive and low throughput
(but highly sensitive and specific) colonoscopy.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.Keywords:
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1.1. Need for an early, non-invasive diagnostic assay for colorectal
cancer
Colorectal cancer (CRC) constitutes the second most
diagnosed cancer, with an estimated 150,000 new cases and
50,000 CRC-related deaths per year in the US (Howlader et al.,
2012). Nearly half of those newly diagnosedwith CRC die within
five years, largely due to late-stage detection of the disease. An
individual's lifetime risk of developing CRC is 6%, with over 90%
of the cases occurring after the age of 50 (Davies et al., 2005).
Consequently, the American Cancer Society recommends
screening every five years for the over 75 million Americans
over the age of 50.
Currently, the gold standard for CRC screening is the
colonoscopy. Although a very effective method for diagnosing
CRC and detecting precancerous polyps, insufficient capacity of
this low throughput test for population-wide screening, along
with cost, discomfort and inconveniences associated with
the procedure, resulted in the screening of only 21–34% of
recommended individuals as of 2004 (Subramanian et al.,
2004; Vijan et al., 2004). Alternatives to the colonoscopy, such
as the fecal occult blood test (FOBT), sigmoidoscopy, and
bariumenemaare also available, but they also each have severe
deficiencies and are not considered to be as effective as the
colonoscopy (Rex et al., 2009). In particular, the widely used
FOBT has a high rate of false positives (~80%) (Ahlquist, 1997;
Doolittle et al., 2001; Davies et al., 2005) as well as a low
sensitivity for cancer and pre-malignant lesions.
Another approach to reducing the high mortality rate of
CRC is to perform an inexpensive and non-invasive screen
as part of a standard general physical examination for the
appropriate population groups (e.g. persons over 50), which
could detect a large fraction of patients who would normally
be missed due to non-compliance. Improved fecal tests are
being developed, for instance, based on molecular profiling of
DNA such as the Exact Science Pre-Gen Plus™ (Berger et al.,
2006); however, such tests have not been widely accepted by
the medical community, potentially due to the emphasis on
home-collection of fecal samples (Woolf, 2004). Yet diagnosing
CRC at an early stage is indispensable as the 5-year survival rate
is around 90% when caught at the localized stage (SEER
Summary Staging) and drops to 70% with regional metastasis
and 12% with distant metastasis (Howlader et al., 2012).
Therefore, an early, non-invasive screen for CRC which can
complement the colonoscopy is urgently needed.
1.2. Serological assays for cancer detection
In contrast to fecal based CRC screening, blood testing based
on detection of multiple biomarkers provides a minimally-
invasive, more patient friendly method of pre-screening for CRC.
One such approach is based ondetection of aberrantmethylation
of CpG-islands (CGI-methylation) in freely circulating DNA in
blood. Epigenomics is developing Epi ProColon, a blood-based
test based on detection of methylation markers in Septin9 (Toth
et al., 2012).
Serum proteins and autoantibodies against tumor-associated
antigens (TAAs) in blood also comprise a potential source of
valuable CRC biomarkers. A 2011 review found 63 studies on theserological diagnosis of CRC with more than 50 TAAs and other
serumprotein biomarkers in development (Creeden et al., 2011).
Autoantibodies to TAAs have been detected in patient's blood
even in the early stages of cancer (Chapman et al., 2008).
Furthermore, autoantibody biomarkers have several advantages
over other serum biomarkers, including long-term stability and
“the inherent amplification of signals provided by the host's own
immune system to low levels of tumor-associated antigens in early
disease” (Anderson and LaBaer, 2005; Storr et al., 2006).
However, any single autoantibody biomarker rarely exceeds
15% diagnostic sensitivity (Zhang et al., 2003; Casiano et al.,
2006; Belousov et al., 2008), thereby highlighting the need to
discover and clinically validate large panels or signatures of TAAs,
in multiplex, as well as to combine autoantibodies with other
serum biomarker types such as circulating proteins, to achieve
both sensitive and specific cancer diagnosis.
1.3. Success of multiplexed bio-assays in genomics
In the genomics realm, highly parallelized and multiplexed
bio-assay technologies such as high density DNA microarrays/
micro-bead arrays (Fodor et al., 1991; Chee et al., 1996;
Gunderson et al., 2004), massively parallel DNA sequencing
(Margulies et al., 2005; Bentley et al., 2008), microfluidic
chips (Dettloff et al., 2008) and bead suspension “arrays”
(Fulton et al., 1997; Lin et al., 2009) have revolutionized
the ability of physicians to provide personalized medical
care. These technologies offer the ability to simultaneously
screen large numbers of analytes using only small sample
volumes, providing for highly effective discovery, validation
and clinical assay of biomarkers for disease diagnosis and
prognosis as well as for the prediction of therapeutic efficacy.
Major successes include genome-wide gene expression profiling
which has led to a new understanding of cellular control
pathways and powerful multiplexed diagnostic/prognostic
tools such as for predicting breast cancer recurrence (e.g. the
Amsterdam 70-gene signature (van't Veer et al., 2002) currently
used in Agendia's FDA-approved MammaPrint® microarray
assay).
1.4. Application of VeraCode™ technology for multiplex serological
immunoassay of colorectal cancer
The utilization ofmultiplexing andmulti-marker signatures
for protein-based serological assays holds great promise in the
realm of cancer diagnostics and prognostics, yet lags behind its
genomic counterpart. Multiplexed bead-based immunoassays
have until nowbeen essentially limited to the Luminex (Austin,
TX) xMAP® technology (Fulton et al., 1997), which has been
used for example to detect antibodies directed against both
viral proteins (Opalka et al., 2003) and parasitic antigens
(Fouda et al., 2006), as well as pneumococcal (Schlottmann et
al., 2006) and meningococcal polysaccharides (de Voer et al.,
2008). Here, we report the development of a novel protein-
based serological immunoassay platform using Illumina's
VeraCode™micro-bead technology. The VeraCode™ system
differs from such existing multiplexed bead platforms in
that it uses digital, 24-bit holographic barcoding for nearly
unlimited potential coding capacity, instead of analog coding
with embedded fluorophores, whose broad spectral emissions
and spectral overlap limit the coding capacity (currently at 500
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theVeraCode™ systemuses a hydrophilic bio-friendly glass bead
surface for low non-specific binding, instead of a hydrophobic
polymeric (e.g. polystyrene) bead surface which can mediate
background in serological assays (Waterboer et al., 2006).
Finally, since the VeraCode™ barcoding is not based on
fluorescence, 2-color fluorescence analyte readout is more
readily implemented on the VeraCode™ system for maximum
flexibility.
By adapting the VeraCode™ digital holographic bead
technology and BeadXpress™ reader, originally developed
by Illumina (San Diego, CA) for genomic applications (up to
384-plex) (Lin et al., 2009), we have developed a novel, high
sensitivity, high throughput and reproducible multiplex
immunoassay approach requiring very low blood sample
volumes. The overall approach is exemplified diagrammatically
in Fig. 1 for detection of autoantibodies to TAAs. We attach
recombinant proteins (antigens) to VeraCode™ beads using
standard chemistries and then perform serum autoantibody
screening from patient blood. Alternatively, in cases where an
antigen is difficult to produce recombinantly, or otherwise
difficult to obtain, it can be produced on-demandwith cell-free
protein expression and rapidly in situ purified onto VeraCode™
beads for subsequent assay. Likewise, sandwich immunoassays
are performed by using a capture antibody instead of an
antigen on the beads and using an anti-analyte detection
antibody (not depicted in Fig. 1). In either case, VeraCode™
beads can be fluorescently read to detect the bound serum
autoantibody or protein biomarker, and decoded using the
BeadXpress™ reader to determine the particular antigen or
capture antibody present on the bead. We show proof-of-
concept in CRC for using a hybrid multiplexed VeraCode™
assay which combines a sandwich immunoassay format for
detection of serumprotein (non-antibody) biomarkers with an
autoantibody assay of TAAs.Fig. 1. Multiplexed serum biomarker profiling on VeraCode™ beads.
Candidate biomarker proteins are expressed in vitro and then attached to
the VeraCode beads. Each protein TAA is attached to a uniquely coded bead.
Various beads are combined and treated with serum/plasma, then detected
by an anti-[human IgG] fluorescently labeled antibody, and finally “read”
and decoded via the BeadXpress™ reader.2. Materials and methods
2.1. Supplies and reagents
EDC(1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide
HCl), Sulfo-NHS (N-Hydroxysulfosuccinimide), MES (2-(N-
Morpholino)ethanesulfonic Acid), EZ-Link Amine-PEO3-
Biotin, EZ-Link-Sulfo-NHS-LC-Biotin, hydroxylamine and
streptavidin were purchased from Thermo-Fisher-Pierce
(Rockford, IL). The PURExpress™ In Vitro Protein Synthesis
Kit was fromNewEngland Biolabs (Ipswich, MA). The TNT® T7
Quick for PCR DNA Rabbit Reticulocyte Cell-Free Expression
Lysate was from Promega (Madison, WI). The DyLight 649
AffiniPureMouse Anti-Human IgG, DyLight 649 AffiniPureGoat
Anti-Human IgG and HRP Conjugated Mouse Anti-Human IgG
antibodies were from Jackson ImmunoResearch Laboratories,
Inc. (West Grove, PA). The Streptavidin R-Phycoerythrin
Conjugate and the recombinant human MAP4K4 protein were
from Invitrogen (Carlsbad, CA). Clones from the Human
ORFeome Collection were purchased from Open Biosystems/
Thermo-Fisher (Huntsville, AL). The pETBlue-2 vector was
from (EMD Biosciences, Inc., San Diego, CA). PD SpinTrap G-25
Columnswere fromGEHealthcare Life Sciences (Pittsburgh, PA).
Carboxyl-terminated VeraCode™ beadswere from Illumina (San
Diego, CA). 400 μL capacity Ultrafree-MCMicro-Centrifuge Filter
Units, Pore Size 0.45 μm Durapore PVDF Membrane and the
Mouse Anti-Carcinoembryonic Antigen (CEA) Capture Antibody,
Clone 1105, were from Millipore (Billerica, MA). The Mouse
Anti-Carcinoembryonic Antigen (CEA) Detection Antibody,
Clone 26/3/13 and recombinant human cyclin B1 (CCNB1)
protein were from Abcam (Cambridge, MA). The CEA standard
protein and ELISAwere fromGenWay Biotech (San Diego, CA).
The Mouse Anti-GDF15 Capture Antibody, Clone 147627, the
Biotinylated Goat Anti-GDF15 Affinity Purified Polyclonal
Detection Antibody, and the Recombinant Human GDF15
Standard Protein were from R&D Systems (Minneapolis, MN).
Nunc-Immuno 96-Well Polystyrene Microtiter Plates, PolySorp,
were from Thermo-Fisher Scientific (Waltham, MA). SureBlue
TMB 1-Component Microwell Peroxidase Substrate was from
KPL (Gaithersburg, Maryland). Recombinant human TP53 (p53)
protein was from Santa Cruz Biotechnology (Santa Cruz, CA).
Recombinant human IGF2BP2/IMP-2/p62 protein was from Sino
Biological (Beijing, China).2.2. Recombinant and cell-free proteins (candidate TAAs)
Human recombinant proteins were purchased commercially
(see Section 2.1: Supplies and Reagents). For cell-free protein
expression, clones from the Human ORFeome Collection
were used as the source for the ORFs. Standard Gateway®
recombination cloning was performed (Walhout et al., 2000)
(Invitrogen, Carlsbad, CA) to transfer the ORFs into a custom
T7 driven cell-free protein expression vector containing a
C-terminal streptavidin binding affinity tag (SBP-Tag; Keefe et
al., 2001) and an N-terminal VSV-G epitope tag. Expression
reactions were performed using one of two transcription/
translation coupled systems, the Rabbit Reticulocyte Lysate
(TNT® T7Quick for PCRDNA), or the PURExpress® E. coli based
reconstituted system, all according to the manufacturer's
instructions. The expression plasmid used was a derivative of
61H.P. Ostendorff et al. / Journal of Immunological Methods 400–401 (2013) 58–69the pETBlue-2 vector containing the aforementioned tags and
sequences for Gateway® cloning.
2.3. Attachment of recombinant proteins and capture antibodies
to VeraCode™ beads
Commercial recombinant proteins, which are supplied in
a variety of formats, concentrations and buffers, were passed
over a PD SpinTrap G-25 Column to remove potentially
incompatible buffer components (e.g. Tris buffer or residual
glutathione used in purifying GST fusion proteins) and to
unify the buffer conditions. In the case where proteins were
supplied lyophilized, they were first dissolved to 1 μg/μL in
water and then supplemented to 1 × PBS, pH 7.5, from a
5 × stock before column purification. The PD SpinTrap G-25
columns were performed according to the manufacturer's
instructions (equilibration in 300 μL 1 × PBS; 70–130 μL
loading of the manufacturer supplied or reconstituted
protein). Following the desalting (buffer exchange), 1/4th
volume of 5 × PBS was added to the eluate to ensure an
adequate buffering capacity of the protein for the subsequent
bead attachment steps. Note that for optimal results with some
proteins (e.g. p53 and MAP4K4), the column buffer exchange
stepwas omitted and themanufacturer supplied proteinswere
simply supplemented to 1 × PBS (either from a 5 × stock or as
detailed above for lyophilized proteins). Note that while a
comprehensive analysis of all possible buffer conditions was not
done, some proteins (e.g. antibodies) coupledmore efficiently to
the VeraCode™ beads using aMES buffering system (0.1 MMES,
pH 4.7, 0.9% NaCl) instead of PBS. In this case, MES buffer
replaced the PBS in the aforementioned steps. Recombinant
protein concentration used for subsequent bead attachment
was typically 0.1 μg/μL in the corresponding buffer (if this
concentration was not possible based on how the protein was
supplied by the manufacturer, concentration was kept as high
as reasonably possible). Capture antibodies to be coupled to
VeraCode™ beads were not desalted, but were simply
supplemented to 1 × concentrated MES Buffer and used at
0.5 μg/μL for subsequent bead attachment.
Recombinant proteins and antibodies were attached to
carboxyl-terminated VeraCode™ beads by a 2-step method.
VeraCode™ beads are 240 × 28 μm, holographically encoded,
glass micro-cylinders with a carboxylated surface chemistry.
First, 10,000 to 40,000 VeraCode™ beads were washed
3 × 800 μL with MES Buffer (0.1 MMES, pH 4.7, 0.9% NaCl)
by sequential mixing, pelleting the beads by brief and
gentle spinning (or allowing beads to settle by gravity)
and removing the supernatant (wash buffer) by manual
pipetting, being careful not to lose the bead pellet. All washes
were performed in this manner unless otherwise indicated.
After discarding the final wash, 200 μL of Sulfo-NHS Buffer
(1 mg/mL in MES Buffer; prepared immediately prior to use)
was added to each washed bead pellet. Beads were mixed
immediately and briefly. 200 μL of EDC Buffer (1 mg/mL in MES
Buffer; prepared immediately prior to use) was immediately
added to each sample (containing both beads and Sulfo-NHS
Buffer) and immediately mixed to combine. Following
incubation for 1 h with mixing (all extended mixing steps
for VeraCode™ beadswere done at 1200 rpmon a VorTemp 56
shaker, Labnet International Inc., Edison, NJ), the beads were
then washed 3 × 800 μL briefly with MES Buffer and then1 × 800 μL quickly with 1× PBS (for proteins or antibodies
prepared in MES Buffer, this PBS wash was omitted). The
protein coupling reaction immediately followed, in which 10–
40 μg of the previously prepared recombinant protein or 100 μg
of antibodywas added to the beads,mixed, and incubated for 1 h
with mixing (a comprehensive titration analysis was not
performed due to the wide range of protein classes and wide
range of concentrations at which they were supplied by the
manufacturers, however, the amounts added are believed to be
sufficient to saturate the bead surface, as using a calculation of
2.5 mg/m2 binding capacity of a solid non-porous surface as
reported for avidin and 15 mg/m2 for antibodies (Plant et al.,
1991), we estimate that 40,000 beads can bind a maximum of
roughly 2–10 μg). Beadswere then spun down, and the protein
solution was removed. The beads were washed 2 × 800 μL
briefly with BSA Block (1% BSA [w/v] in TBS-T; TBS = 50 mM
Tris, pH 7.5, 200 mM NaCl; TBS-T contains 0.05% [v/v]
Tween-20) before discarding the wash and incubation with
an additional 400 μL of BSA Block for 30 min. Beads were
then washed briefly 1 × with 800 μL of PBS-1 M NaCl,
1 × 30 min with 400 μL of PBS-1 M NaCl (with shaking)
and then 2 times briefly with 800 μL TBS-T. Beads were
stored in TBS-T at 4 °C.
2.4. Expression and attachment of cell-free produced proteins to
VeraCode™ beads
For optimal performance, we used an indirect method of
coating VeraCode™ beadswith biotin followed by streptavidin.
Streptavidin beads were then used to in situ capture/purify
cell-free produced proteins carrying the SBP-Tag (Keefe et al.,
2001), directly from the crude expression reaction. First, a vial
of 20,000 carboxyl-terminated VeraCode™ beads was washed
5 × 400 μL with MES Buffer (0.1 M MES, pH 4.7, 0.9% NaCl).
After discarding the finalwash, 200 μL ofMES Bufferwas added
to each washed bead pellet. To this, 25 μL of 48 mM EZ-Link
Amine-PEO3-Biotin stock was added. Beads were mixed
immediately and briefly. Next, 25 μL of EDC Buffer
(100 mg/mL in water; prepared immediately prior to use)
was immediately added to each sample (containing both beads
and Biotin-Amine Linker), mixed, and incubated for 1 h with
mixing. Beads were then spun down, and the reaction solution
was removed. The beads were washed 4× 400 μL (5 min each)
with Quench Buffer (10 mM hydroxylamine in PBS-T; prepared
immediately prior to use; PBS-T is standard PBS buffer with
0.05% [v/v] Tween-20) before discarding the wash and
incubation with an additional 400 μL of Quench Buffer for
30 min. Beads were then further washed briefly 2 × with
400 μL of PBS containing 1 M NaCl (first wash brief and
then leaving in the second wash for 1 h with mixing).
Finally, beads were washed 4× 400 μL briefly with TBS-T.
Beads were stored, protected from light, in TBS-T at 4 °C.
Before coating with Streptavidin, Biotin-VeraCode™ beads
were pre-treated 2 × 5 min using 400 μL of BSA Block with
mixing. After removing the Block, 250 μL Streptavidin solution
(1 mg/mL in BSA Block) was added and incubated for 30 min
with mixing. After removing this solution, beads were washed
3 × 400 μL with TBS-T, followed by 5 min washes of
3 × 400 μL with TBS containing 1 M NaCl. Finally, beads
were washed briefly 3 × 400 μL with TBS and stored at +4 °C
in this buffer.
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SBP-Tag (Keefe et al., 2001) using a cell-free system according
to the manufacturer's instructions (Rabbit Reticulocyte or
PURExpress™; see Section 2.2 of Materials and methods).
25 μL of cell-free protein expression reaction was mixed with
an equal volume of BSA Block and clarified by 1 min in a
standard micro-centrifuge (15,000 rpm) followed by passing
through a 0.45 micron pore size spin filtration device (400 μL
capacity Ultrafree-MC Micro-Centrifuge Filter Units, Pore Size
0.45 μm Durapore PVDF Membrane). The aforementioned
streptavidin VeraCode™ beads were pelleted, briefly washed
3 × 400 μL in TBS-T followed by 2 × 5 min each with BSA
Block. Next, the diluted cell-free protein expression reaction
was added and mixed 30 min for protein capture (note that
this amount of cell-free protein expression reaction is used for
a minimum of 500 beads and a maximum of 5000 beads).
Protein capture was followed by 4 × 400 μL brief washes with
TBS-T before the beads were re-suspended to their original
concentration in TBS-T. Beads were stored in TBS-T at 4 °C
protected from light.
2.5. Biotin labeled detection antibodies for VeraCode sandwich
immunoassays
While the biotin labeled anti-GDF15 antibody used in
the VeraCode™ assays was from a commercial source (see
Section 2.1: Supplies and Reagents), the anti-CEA antibody
used in the VeraCode™ assays was biotin labeled in-house as
follows: The commercial antibody as supplied (see Section 2.1:
Supplies and Reagents) was prepared to 1 mg/mL (100 μg
used) and supplemented to 100 mM sodium bicarbonate from
a 1 M stock. A high concentration 10 mM stock of EZ-Link-
Sulfo-NHS-LC-Biotin was prepared fresh and the appropriate
volume immediately added to the antibody to yield a 15-fold
molar excess. The reaction was carried out for 30 min with
gentle mixing. The reaction was then quenched by adding 1/9th
volume of 200 mM glycine in 200 mM sodium bicarbonate and
200 mM NaCl and subsequently mixing for 15 min. To avoid
losses in the subsequent desalting column, a BSA carrier was
then added from a 10% (w/v) stock to yield a final 0.05% (w/v).
To remove unreacted biotin, the reaction mix was then desalted
on PD SpinTrap G-25 columns. The PD SpinTrap G-25 columns
were performed according to the manufacturer's instructions
(equilibration in 300 μL of TBS). Following the desalting (buffer
exchange), 1/9th volume of 10× TBS was added to the eluate to
ensure an adequate buffering capacity.
2.6. Serological assay on VeraCode™ beads
Colorectal cancer and normal sera/plasma samples were
from Asterand Inc. (Detroit, MI), ProMedDx, LLC (Norton,
MA), the Ontario Institute of Cancer Research (OICR) and
Analytical Biological Services Inc. (Wilmington, DE). Colorectal
cancer patient samples were an approximate 50:50 distribution
of a) stage T2 or T3 (AJCC staging) non-metastatic and b) stage
T3 or T4 metastatic.
To perform a multiplexed bead experiment, beads with the
different proteins and/or capture antibodies, each identifiable
by a unique holographic barcode, were pooled into a round
bottom 96-well polypropylene microtiter plate. Kitting was
done according to Illumina's (San Diego, CA) standard protocolexcept that TBS-T was used at all kitting steps and 30 min is
allowed for beads to settle into wells (typically 30–50 beads of
each species per well). Human serum/plasma samples (diluted
at 1/50 in BSA Block for TAA validation studies or diluted 1/10
for the hybrid 3-Plex p53 TAA and GDF15/CEA sandwich
immunoassay) were added at 100 μL/well and shaken for
30 min. Samples were removed and beads were washed
6 × 250 μL briefly with BSA Block. For TAA validation studies,
beads were then probed with 100 μL of an Anti-Human IgG
Fluorescent (DyLight 649) Secondary Antibody diluted to
10 μg/mL in BSA Block. Probing was for 30 min with mixing.
The probe solution was removed and discarded, and the beads
washed 6 × 250 μL briefly with TBS-T. The final wash solution
was discarded, leaving the bead pellets and a small residual
liquid volume in the wells of the readout plate (~70 μL). Beads
were scanned using the BeadXpress™ reader (Illumina, San
Diego, CA). For the aforementioned hybrid 3-plex assay, biotin
labeled anti-GDF15 (0.05 μg/mL) and anti-CEA (1 μg/mL)
antibodies were first added (together) in BSA Block
immediately after the serum/plasma (and subsequent wash)
step. Probing was for 30 min with mixing. The probe solution
was removed and discarded, and the beads washed 6 × 250 μL
brieflywith TBS-T. Probingwith the Anti-Human IgG Fluorescent
(DyLight 649) Secondary Antibody and subsequent washing
were then performed as described above. Finally, the beadswere
probed with Streptavidin R-Phycoerythrin for 30 min with
mixing at 10 μg/mL in BSA Block, washed 6 × 250 μL briefly
with TBS-T and scanned in the BeadXpress™ reader as described
above. Straight sandwich immunoassays for GDF15 andCEA (but
no TAA detection) were performed in the same manner except
that the Anti-Human IgG Fluorescent (DyLight 649) Secondary
Antibody probing was omitted.
2.7. ELISA analysis of TAAs and circulating non-antibody protein
biomarkers
The p53 autoantibody (TAA) ELISA was performed similar to
published reports (Zhang et al., 2003). Briefly, the recombinant
protein was diluted to 0.5 ng/μL in PBS and 100 μL used to
passively coat eachwell of a 96-well polystyrenemicrotiter plate
(Nunc-Immuno 96-Well Plates, PolySorp). Plates were then
washedwith TBS-T and pre-treatedwith BSA Block. Sera/plasma
samples were diluted to 1/100 in BSA Block and 100 μL added to
the wells for 30 min incubation. Detection was with an HRP
conjugated mouse anti-human IgG antibody followed by
development with SureBlue TMB 1-Component Microwell
Peroxidase Substrate. The CEA sandwich ELISA was performed
according to the manufacturer's instructions (see Section 2.1:
Supplies and Reagents).
3. Results
3.1. Attaching proteins to VeraCode™ beads
Recombinant proteins were directly and covalently attached
to VeraCode™ beads using standard carbodiimide (EDC)
chemistries to link amine groups on the proteins to the carboxyl
groups on the beads. In the case of cell-free expressed proteins,
they were affinity captured directly from the crude expression
reactions by their C-terminal SBP-Tag (Keefe et al., 2001) onto
streptavidin coated VeraCode™ beads. For preparation of
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not shown) were obtained by first attaching a biotin-amine
linker to the carboxyl beads using the aforementioned
carbodiimide chemistry, followed by attachment of (tetrameric)
streptavidin to the biotinylated beads. With either recombinant
or cell-free proteins, successful attachment of the proteins to the
beads is readily verified (quality controlled) by detection of
epitope or fusion tags present in the proteins. An example of this
quality control measure is shown in Supplementary Fig. 1 with
the p53 and MAP4K4 proteins. Detection of recombinant
proteins was via a GST fusion tag in this case and cell-free
proteins via their N-terminal VSV-G epitope tag. With the
recombinant proteins, signal to background ratios were
250:1 and 125:5 for p53 and MAP4K4 respectively, and for
the cell-free proteins 34:1 and 87:1 (note that all DNA clones
used to produce cell-free proteins were sequence verified).
3.2. Validate ability to detect TAAs on VeraCode™ beads by
comparison to ELISA
First, human p53 (TP53) (Koziol et al., 2003; Saleh et al.,
2004; Nozoe et al., 2007; Reuschenbach et al., 2009) was
validated as a positive control TAA using a conventional ELISA
to detect autoantibodies in the serum/plasma of 47 healthy
(normal) and 47 colorectal cancer patient samples (94 total
patient samples) (Fig. 2, top panel). To calculate cutoffs, the
ELISA values were log2-transformed (to achieve better Gaussian
distribution of the data) and the standard deviation across the
normal patient cohort was calculated. A diagnostic scoring cutoff
set at 3 standard deviations above the mean for the normal
patient cohort yielded 11% sensitivity for colorectal cancer
detection at 100% specificity with these samples. This
method of setting cutoffs is commonly used for autoantibody
immunoassays (e.g. Liu et al., 2009).
Next, to technically validate the VeraCode™ bead assay
using the p53 TAA, we evaluated the data obtained from
screening the same patient cohort against beads to which
either purified recombinant p53 or cell-free produced p53 was
attached (Fig. 2, middle and bottom panels, respectively). The
cutoff and scoring were done as with the ELISA. The error bars
represent the intra-assay bead-to-bead variance in fluorescence
intensity within each sample-protein pair (i.e. variance of
replicate beads). Results from ELISA were compared to results
obtained fromVeraCode™ beads. All 5 colorectal cancer samples
which scored positive in the ELISA also score positive on both
VeraCode™ bead assays (with both recombinant and cell-free
p53 protein). In addition, two additional hits in the CRC cohort
were detected by the VeraCode™ assay (same two patients
detectedwith both recombinant and cell-free proteins) but 100%
specificity versus the normal patients was maintained.
3.3. Reproducibility of multiplex VeraCode™ immunoassays
In order to establish intra-assay precision, we performed
the multiplex bead assay on triplicate samples of four CRC
and four normal patient sera/plasma in a 96-well plate. Two
TAAs were used in this multiplexed experiment: The p53
control (discussed earlier) and Cyclin B1 (Koziol et al., 2003;
Chen et al., 2007; Reuschenbach et al., 2009). Each of the
three replicate wells of each sample contained approximately
50 beads per TAA. Two previously known p53-positive sera(based on ELISA and VeraCode™ data in Fig. 2) were chosen
for this experiment, whereas their sero-reactivity against
CyclinB1 was not known a priori (i.e. positives not necessarily
expected based on low diagnostic sensitivity of individual
TAAs). Results are shown in Supplementary Fig. 2. An average
intra-assay CV of 10% across all samples and proteins was
achieved (see error bars in Supplementary Fig. 2 for more
detail). The diagnostic scoring cutoff for p53 was calculated
based on the normal samples as discussed earlier, however, for
maximum stringency, the calculations were done before
averaging the MFI values of the replicate samples (MFI =
Mean Fluorescence Intensity; i.e. mean of all beads within
one sample per TAA). With this, the scoring cutoff accounts
for variance across the sample replicates. Of note, using this
cutoff, previously known p53-positive samples were correctly
detected in this VeraCode™ bead experiment, with no false
positives (neither in CRC nor normal samples).
Likewise, to define inter-assay reproducibility, we ran and
compared three independent assays (on three different days)
on the same lot of p53 VeraCode™ beads using a 94-member
training set of plasma/serum samples (47 normal and 47
CRC) (Supplementary Fig. 3). Again, the scoring cutoff was
determined by the non-averaged, replicate MFI values, resulting
in amore stringent analysis (i.e. MFI values of the three different
assay runs for the normal patient samples were not averaged
before determining cutoff). Results are shown in Supplementary
Fig. 3. Despite this stringent cutoff, all five previously known
p53-positive samples (based on ELISA in Fig. 2) remained
positive on the VeraCode™ beads in this rigorous inter-assay
setting. Furthermore, the two additional p53-positives picked up
only by the VeraCode™ assay (and not ELISA) shown in Fig. 2
(single assay), also remained positive in this rigorous inter-assay
setting. The average inter-assay CV was 20% across all sample-
protein pairs (see error bars in Supplementary Fig. 3 for more
detail).
Finally, as an additional metric of inter-assay reproducibility,
linear regression analysis of two separate assay runs of the 94
samples for twodifferent TAAs (assayed inmultiplex) showedR2
values≥0.96 in both cases (Supplementary Fig. 4; p53, aswell as
insulin-like growth factor 2 mRNA binding protein 2 [IGF2BP2]
(Reuschenbach et al., 2009)).
3.4. Improved sensitivity for CRC using hybrid multiplexed
VeraCode™ assay of autoantibodies and serum proteins
Next, to show compatibility of the VeraCode™ based
assay with multiple biomarker classes and to increase the
overall diagnostic sensitivity for CRC beyond TAAs alone, we
combined three distinct biomarkers, i) autoantibodies against
the aforementioned p53 TAA, aswell as detection of serum levels
of ii) carcinoembryonic antigen (CEA) and iii) the cytokine
GDF15. While CEA is very well known as a CRC biomarker for
diseasemonitoring andprognostics, its diagnostic use alone or as
part of a biomarker panel is currently under investigation
(Creeden et al., 2011; Su et al., 2012). GDF15 (MIC-1) is perhaps
not as well as established for CRC, however, several recent
studies suggest it may be useful as a prognostic and diagnostic
marker (Xue et al., 2010;Wallin et al., 2011; Brown et al., 2012).
First, we sought to demonstrate that sandwich immunoassay
detection of non-antibody serum protein biomarkers could also
be achieved on the VeraCode™ system. Aswith the p53 TAA, this
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Fig. 2. Validate VeraCode™ immunoassay using the p53 TAA and comparing to ELISA with colorectal cancer patients. Results from ELISA (top panel) were
compared to results obtained from VeraCode™ beads coated with either purified recombinant p53 (middle panel) or cell-free produced p53 which was in situ
purified on the beads (bottom panel). Protein TAAs were bound to the VeraCode™ carboxyl beads as depicted in the inset diagrams and the beads used to assay
patient serum/plasma for the presence of autoantibodies. MFI = Mean Fluorescence Intensity of the BeadXpress™ instrument readout. Individual patient
samples are denoted on the x-axis whereby the prefixes CRC = Colorectal Cancer and N = Normal (Healthy Individuals). The overall CRC and normal patient
cohorts are also labeled below the x-axis. Error bars represent standard deviation of replicate wells in the ELISA or replicate beads in the VeraCode™ assay. The
red horizontal lines on the graphs indicate the diagnostic scoring cutoffs (based on log2 data). The black vertical bars are positive samples.
64 H.P. Ostendorff et al. / Journal of Immunological Methods 400–401 (2013) 58–69was done by comparison to conventional ELISA. In this case CEA
was used as amodel system (with 52 CRC and 25 normal serum/
plasma samples). For the VeraCode™ assay, an anti-CEA capture
antibody was attached to the bead surface. Following incubation
with the serum/plasma samples to capture the CEA,
detection was with a biotin labeled anti-CEA antibody
followed by a fluorescently labeled streptavidin. ELISA
(sandwich immunoassay format) was simply performed using a
commercially available kit (see Materials and methods). Results
are shown in Fig. 3. Clear agreement is apparent between the
two assays as seen by the overlaid bar graphs in Fig. 3A. By
setting a cutoff for each assay based on the normal patient cohort
(as previously described) in order to score positive CEA “hits”,
90% concordancewas observedbetween the ELISA andVeraCode
™ assays in the CRC patient cohort, with 100% specificity in both
cases in the normal patient cohort.
To assess quantitative concordance of the signal magnitudes
of each assay, a linear regression was performed as shown inFig. 3B. An R2 value of 0.9 was obtained in this case with one
clear outlier which yielded an abnormally high signal in the
VeraCode™ assay. Eliminating this outlier yields an R2 value of
0.96.
Next, in order to assay these two distinct biomarker types
(autoantibodies to TAAs and non-antibody serum proteins)
in multiplex, we formatted a novel hybrid assay on the
VeraCode™ platform. p53 TAA beads for autoantibody
detection were configured as before. For detection of the
non-antibody serum proteins, the beads were configured for
a sandwich immunoassay by attaching capture antibodies
for CEA and GDF15 on different barcoded bead species.
Following incubation of the pooled beads with the serum/
plasma samples (to capture either anti-p53 autoantibody,
CEA or GDF15), detection of bound autoantibody was with a
fluorescently labeled monoclonal mouse anti-[human IgG]
secondary antibody, which was chosen for its lack of cross-
reactivity with mouse IgG (i.e. the CEA and GDF15 capture
Fig. 3. Concordance of ELISA and VeraCode™ for detection of circulating protein markers such as CEA in CRC. (A.) Results from ELISA (blue bars) were compared
to results obtained from VeraCode™ beads (black bars). Both assays were formatted as a sandwich immunoassay whereby serum/plasma CEA protein was bound
to the ELISA plate or bead surface by a monoclonal anti-CEA capture antibody, followed by detection using a labeled anti-CEA antibody targeting a different
epitope than the capture antibody, as depicted in the inset diagram for the VeraCode™ beads. MFI = Mean Fluorescence Intensity of the BeadXpress™
instrument readout. Individual patient samples are denoted on the x-axis whereby the prefixes CRC = Colorectal Cancer and N = Normal (Healthy Individuals).
The overall CRC and normal patient cohorts are also labeled below the x-axis. The black dotted and blue horizontal lines on the graph indicate the diagnostic
scoring cutoffs for each assay (based on log2 data). The red asterisks represent the only discordant hits, which were borderline positive or negative CRC samples
that fell extremely close to the cutoffs. (B.) Linear regression analysis comparing VeraCode™ bead results, plotted on the y-axis in MFI, with ELISA results, plotted
on the x-axis in pg/mL. The R2 value is 0.96 excluding one outlier (0.90 if the outlier, noted by the red circle, is included).
65H.P. Ostendorff et al. / Journal of Immunological Methods 400–401 (2013) 58–69and detection antibodies). Detection of the bound CEA and
GDF15 proteins was with corresponding biotin labeled
detection antibodies followed by a fluorescently labeled
streptavidin. Importantly, owing to the unique 2-color
fluorescent readout capabilities of the BeadXpress™ reader,
autoantibody detection and CEA/GDF15 detection could be
achieved with different colors (DyLight™ 649 at 670 nm
emissions and R-Phycoerythrin at 578 nm emissions,
respectively). This adds an extra measure of assurance
that if any cross-reaction between the autoantibody and
sandwich immunoassay systems were to occur, it would not
generate a signal (e.g. if the anti-[human IgG]were to cross-react
with the CEA or GDF15 beads, this could be distinguished from
true CEA or GDF15 signal on the basis of the fluorescence color).
Nonetheless, a critical first step was to confirm that these
three biomarkers could indeed be multiplexed without cross-
reaction or interference among the various capture and
detection agents. As a first step, since recombinant protein
standards are available for CEA and GDF15, the standards were
spiked into BSA Block buffer (see Materials and methods) to
create high and low positive samples in the VeraCode™ assay.A series of single-plex measurements were performed to test
all possible permutations of capture antibody bead species,
analyte (CEA or GDF15) and detection antibody. Results are
shown in Fig. 4A. As seen, a positive, dose dependent signalwas
only observed in cases where the correct capture and detection
antibodies were matched with the correct analyte, and no
signal when mismatched (the blank, corresponding to buffer
without analyte, also yielded no signal).
Since for the p53 autoantibody detection there is no
standard protein which can be used (since the analyte is the
serum autoantibody), the full 3-plex assay (CEA, GDF15 and p53
autoantibody) was compared to single-plex measurements for a
variety of knownpositive andnegative samples spanning a range
of signals, in order to confirmmultiplexing compatibility. A linear
regression analysis between the single-plex and 3-plex assays is
shown in Fig. 4B, yielding an R2 value≥0.98 for all 3 biomarkers.
To show the specificity of thismetric, a linear regressionbetween
3-plex measurements of GDF15 and p53 autoantibody, in which
no correlation is expected, yields an R2 value of 0.04.
Finally, in a culmination of these efforts, the full 3-plex
assay was performed on 186 CRC and normal patient
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Fig. 4. Development of a hybrid multiplex assay for autoantibodies (TAAs) and circulating proteins. A hybrid VeraCode™ Bead™ assay for multiplexed detection
of serum autoantibodies to the p53 TAA (antigen–antibody assay format) as well as detection of the circulating serum proteins CEA and GDF15 (sandwich
immunoassay format) was developed. (A.) To verify the sandwich immunoassay portion of the assay could be multiplexed, recombinant CEA or GDF15 standard
proteins were spiked into buffer to create high and low positive samples (see x-axis; blank is just buffer). All possible combinations of capture antibody beads,
detection antibody and analyte (CEA or GDF15 samples) were tested in a series of single-plex assays to verify lack of cross-reaction. (B.) To verify the p53
autoantibody assay could be fully multiplexed with the CEA and GDF15 sandwich immunoassays, a 3-plex VeraCode Bead™ assay was performed using a range of
positive and negative sera/plasma for each analyte, and the results for each biomarker from the 3-plex assay (y-axis) were plotted by linear regression against the
single-plex results (x-axis). To show the specificity of this metric, a linear regression between 3-plex measurements of GDF15 and p53 autoantibody, in which no
correlation is expected, was also performed (lower right).
66 H.P. Ostendorff et al. / Journal of Immunological Methods 400–401 (2013) 58–69serum/plasma samples (59 normal and 127 CRC) (Fig. 5A).
Using the aforementioned cutoff and scoring method,
individually, CEA, GDF15 and the p53 TAA were 21%, 38%
and 11% sensitive and 98%, 100% and 100% specific, respectively.
Composite sensitivity and specificity of all 3 biomarkers in the
multiplexed assay were 54% and 98%, respectively and
biomarker overlap (or lack thereof) is shown in the Venn
Diagram in Fig. 5B. Notably, while partial redundancy is
observed, each biomarker detects several CRC patients that
the other biomarkers do not (9, 11 and 29 unique patients
for p53, CEA and GDF15, respectively).
4. Discussion
Here we demonstrate the novel adaptation of Illumina's
multiplexed, genomic, VeraCode™ micro-bead technology
for high-throughput immunoassay and validation of two
classes of serological biomarkers: autoantibodies to TAAs
(see Fig. 1) and circulating non-antibody proteins, using
colorectal cancer (CRC) as a model system. We have created a
multiplexed “hybrid” assay for the simultaneous detection of
these two classes of serological biomarkers. To our knowledge,
this is the first report of use of the VeraCode™micro-beads as a
protein/immunoassay platform. The potential advantages of
this assay include its requirement for only a small volume
of blood, the ability to multiplex and perform this in ahigh-throughput manner, and the ability to add in new
biomarkers to eventually achieve a higher level of sensitivity
while maintaining a high specificity for CRC diagnosis. Our goal
is to continue to add to and refine our 3-marker CRC panel,
thereby creating an effective CRC diagnostic screening test,
which would be predicted to have excellent compliance due to
its non-invasive nature. This approach could be used as a
targeted population-wide screening test (for people over 50), or
could eventually replace the colonoscopy altogether, assuming
that the appropriate level of sensitivity and specificity is achieved
by the expansion of our CRC biomarker panel.
Another use for this novel protein-based platform could be
for the high-throughput clinical validation studies which are
urgently needed for the constant stream of newly reported
putative serological biomarkers. For example, emerging
proteomic techniques such as high density proteinmicroarrays
(Hudson et al., 2007; Babel et al., 2009; Anderson et al., 2011)
have greatly accelerated the pace at which candidate TAAs are
currently being discovered. However, a major bottleneck is the
rigorous clinical validation of these candidates in order to
establish their true clinical utility and significance. A high-
throughput validation method is desperately needed for testing
the plethora of discovered or partially validated serological
biomarkers, such as TAAs, which are being reported for various
cancers with potential use in diagnostics (Reuschenbach et al.,
2009; Creeden et al., 2011).Whenmoving to clinical studies on
56
7
8
9
10
11
12
13
11
12
13
14
15
16
17
Lo
g 2
 
M
FI
 (C
EA
)
Lo
g 2
 M
FI
 (p
53
 &
 G
DF
)
Biomarker
Normal
CRC
3SD Cutoff
p53
p53 CEA
GDF
0
3 14
29
119
2
A B
CEAGDF15
Fig. 5. Diagnostic performance of a three marker CRC assay combining autoantibody (TAA) and circulating protein detection. (A.) 3-plex recombinant TAA and
soluble protein assay on VeraCode™ beads was performed on 186 patient samples (59 normal and 127 CRC). Protein TAAs were bound directly to the VeraCode™
carboxyl beads and used to assay patient serum/plasma for the presence of autoantibodies, while capture antibodies were bound to VeraCode™ carboxyl beads to
assay for circulating protein markers. Individual markers are denoted on the x-axis. Individual patient samples are denoted by green circles (healthy individuals)
and red circles (colorectal cancer patients). MFI = Mean Fluorescence Intensity of the BeadXpress™ instrument readout (log2 data shown). The black dotted
lines indicate the diagnostic scoring cutoffs, set at 3 standard deviations above the mean of the normal patients. CEA, GDF15 and the p53 TAA were 21%, 38% and
11% sensitive and 98%, 100% and 100% specific, respectively. Composite sensitivity and specificity of all 3 biomarkers in the multiplexed assay were 54% and 98%,
respectively. (B.) Venn diagram demonstrating the number of “hits”, or CRC patients which tested positive, specific to each biomarker. The overlap of circles
indicates patients that were detected by more than one biomarker.
67H.P. Ostendorff et al. / Journal of Immunological Methods 400–401 (2013) 58–69very large and diverse patient populations, it would be desirable
to screen as many candidate TAAs as practical, since diagnostic
performance of biomarkers under these rigorous conditions
cannot always be predicted (in fact, a greatmany biomarkers fail
at this stage). Furthermore, it is increasingly clear that due to the
heterogeneity of human cancers, panels or signatures of
biomarkers, including different classes of biomarkers, will
be required for optimal diagnostic performance in the ultimate
clinical assay. The VeraCode™ bead-based, multiplexed, solid-
phase immunoassaymethod reported here is ideally suited both
for clinical validation and diagnostic detection of serological
biomarker panels or signatures, including autoantibodies against
TAAs as well as non-antibody protein biomarkers.
Technical validation of the tumor biomarker assay itself is
a critical step in the development of clinical test (Marchio et
al., 2011). We first validated the VeraCode™ technology for
serological immunoassays by comparison to the gold standard
and clinically accepted ELISA method. For detection of
autoantibodies against TAAs, VeraCode™ results obtained
using both a commercial recombinant or a cell-free produced
p53 protein compared well to the ELISA data (96% “hit”
concordance in CRC) confirming the validity of the method.
Indeed, the only discordance occurred where the VeraCode™
immunoassayswere able to reproducibly detect two additional
low-positive, statistically valid CRChits (4% increase in diagnostic
sensitivity). This increased sensitivity is likely the result of
decreased background in the normal patient samples relative to
the p53-positive samples, particularly with the recombinant
protein (see Fig. 2middle panel). A basis for this low background
may be the relatively “bio-friendly”, hydrophilic glass bead
surface as opposed to the hydrophobic polystyrene ELISA plates.As additional technical validation, it should be noted that
the overall diagnostic sensitivity of the p53 VeraCode™ assay
for CRC (15% in above experiments) is in excellent agreement
with literature reports (average of 8% and maximum of 24%
sensitive in systematic survey (Reuschenbach et al., 2009)).
Finally, intra- and inter-assay CVs of the VeraCode™ TAA
assays were strong at 10% (48 total data points) and 20% (282
total data points), respectively. While the inter-assay CVs
were acceptable, future improvements in reproducibility may
be achieved with the development of rigorous assay-to-assay
normalization controls and with better mixing approaches
for the large and relatively dense 240 micron glass beads
(cylinders), which tend to settle quickly and may result in
poor and inconsistent mixing and binding kinetics.
Likewise, the VeraCode™ system was also technically
validated against ELISA for detection of non-antibody circulating
protein biomarkers using a sandwich immunoassay format. In
this case, the CRC biomarker CEA was used as a model system.
Here, 94% hit concordance was seen between the two assay
types in 52 CRC samples (and quantitative correlation of R2 =
0.9 when a linear regression is performed between the assays).
Not surprisingly, the only discordant hits were borderline
positive or negative CRC samples that fell extremely close to the
cutoffs (see red asterisks in Fig. 3A), as the consistently low
background in the normal patients resulted in a very low
scoring cutoff (both assays show 100% specificity against
normal samples).
Next, by combining the most robust TAA observed in our
studies, p53, with sandwich immunoassay based quantification
of the well-known CRC biomarker CEA, and the cytokine
GDF15 in a hybrid multiplexed assay, we achieved a
68 H.P. Ostendorff et al. / Journal of Immunological Methods 400–401 (2013) 58–69composite diagnostic sensitivity and specificity of 54% and
98%, respectively (186 samples CRC and normal). Thus, we
demonstrate the ability to measure, in multiplex, two distinctly
different biomarker types using different assay formats,
simultaneously, on the VeraCode™ beads. As with the TAAs
alone, the additive benefit of combing multiple biomarkers
stems from the lack of complete redundancy, with each
biomarker detecting several patients (9 to 29) which the
others did not, and with no single biomarker exceeding 38%
sensitivity (GDF15).
It is important to emphasize that while the particular
biomarkers used here were chosen to exemplify the
immunoassay method, the clinical studies performed here
were only preliminary, retrospective validation studies on a
particular cohort of CRC and normal patient samples, and that
the results of these studies would need further validation using
larger patient cohorts, as well as non-target disease controls
(e.g. inflammatory bowel disease and cancers other than CRC)
and ultimately, blinded studies and prospective clinical studies.
In the future, it is expected that the CRC biomarker panel not
only would expand, but also would be refined through
elimination of biomarkers as further studies are performed
using the VeraCode™ immunoassay methods presented here.
For example, GDF15 is a stress-induced cytokine and in addition
to CRC has been shown to be a biomarker for a variety of
conditions such as heart disease (reviewed in Wollert and
Kempf, 2012) andworsening albuminuria in patientswith type 2
diabetes (Hellemons et al., 2012).
In conclusion, we have demonstrated the VeraCode™
bead platform provides the basis for a robust, sensitive,
accurate and high throughput test for multiplexed biomarker
detection, as well as for the eventual clinical diagnostic assay
which could be employed for biomarker signatures or panels.
We anticipate that addition of more biomarkers to the assay
could ultimately provide the necessary diagnostic performance
for non-invasive population-wide CRC screening which could
complement the expensive, slower and more invasive
colonoscopy.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jim.2013.09.013.
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